| Autor: |
Bandara LR; Prolifix Ltd, London, UK., Girling R, La Thangue NB |
| Jazyk: |
angličtina |
| Zdroj: |
Nature biotechnology [Nat Biotechnol] 1997 Sep; Vol. 15 (9), pp. 896-901. |
| DOI: |
10.1038/nbt0997-896 |
| Abstrakt: |
A variety of studies implicate the E2F transcription factor as a critical regulator of the mammalian cell cycle. The E2F pathway is aberrant in most, if not all, human tumor cells; therefore, therapeutic regimes that modulate E2F activity may provide an approach for reinstating growth control in situations where normal physiological control is lost. To elucidate the role of E2F in the cell cycle and assess its value as a therapeutic target, we have introduced peptides that functionally antagonize E2F DNA binding activity into mammalian cells. Introduction of these peptides into mammalian tumor cells caused the rapid onset of apoptosis, an outcome that correlates with the inactivation of physiological E2F. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
